Abiraterone in the treatment of metastatic castration-resistant prostate cancer

Androgen deprivation therapy remains the single most effective treatment for the initial therapy of advanced prostate cancer, but is uniformly marked by progression to castration-resistant prostate cancer (CRPC). Residual tumor androgens and androgen axis activation are now recognized to play a prom...

Descripción completa

Detalles Bibliográficos
Autor principal: Mostaghel, Elahe A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912049/
https://www.ncbi.nlm.nih.gov/pubmed/24501545
http://dx.doi.org/10.2147/CMAR.S39318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912049/
https://www.ncbi.nlm.nih.gov/pubmed/24501545
http://dx.doi.org/10.2147/CMAR.S39318

Ejemplares similares